 Remidio Innovative Solutions has been recognised among the top 3 in AI by HER Challenge at the India AI Impact Summit 2026. The India AI Impact Summit, the world’s largest AI summit, brought together innovators, policymakers, and industry leaders to spotlight AI solutions driving real-world societal impact. The AI by HER Challenge was specifically designed to recognise women-led teams developing impactful AI solutions across sectors including health diagnostics, precision nutrition, talent intelligence, and MSME enablement.
The AI by HER Award was part of a global impact challenge and was one of the three flagship events of the India AI Impact Summit 2026. The challenge witnessed an overwhelming response, receiving over 4,500 applications from more than 50 countries, making it one of the most competitive and internationally diverse AI platforms focused on real-world societal impact.
At the heart of Remidio’s recognition is the Medios HI (Humanizing Intelligence) AI platform, which runs entirely on-device, offline, and delivers screening results for three of the most common causes of preventable blindness: diabetic retinopathy (DR), glaucoma, and age-related macular degeneration (AMD). A single tap on Remidio’s Fundus on Phone (FOP NM 10) camera delivers results for all three conditions in a few seconds, without requiring internet connectivity or specialist training.
The clinical performance of Remidio’s AI has been validated through multiple independent, prospective studies published in peer-reviewed journals including JAMA Ophthalmology, Nature Eye, and the Indian Journal of Ophthalmology.
All three AI algorithms were the first to receive CDSCO approval. Additionally, Remidio’s Medios HI Glaucoma AI and Medios HI DR AI have received CE Marking as Class II Software as a Medical Device (SaMD) under the EU Medical Device Regulation (MDR), and the company’s devices are FDA 510(k) registered in the United States. This regulatory trifecta positions Remidio as one of the most comprehensively approved ophthalmic AI platforms globally.
“As chronic diseases surge globally, Remidio sits at the intersection of medtech, AI, and population health, and preventing blindness is only the beginning. Our next frontier is oculomics, using the eye as a window to detect systemic disease across the body,” said Dr. Anand Sivaraman, CEO and founding director, Remidio Innovative Solutions.
|